European Union6 days leftNon-profit, Private Business, Research Institution, Public Institution, Other
Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction
Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction
Funding Amount
€20.2M - €20.2M
Deadline
09/10/2025
Eligible Organization Types
Non-profit, Private Business, Research Institution, Public Institution, Other
Trusted by
What is the Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction Call?
Grant Description
This call supports research and innovation actions to adapt and extend an existing federated multimodal data platform for transdiagnostic stratification of central nervous system driven symptoms of reward/motivation and impulsivity across Alzheimer’s disease, major depressive disorder and obesity. It aims to identify and validate novel quantitative biological markers and endpoints, develop a roadmap for regulatory and clinical adoption, and prepare the healthcare system through stakeholder colla...
Required Results for Successful Funding
Expected Outcomes
1. A sustainable, collaborative large multimodal data platform that identifies novel transdiagnostic candidate markers and endpoints for reward/motivation and impulsivity (RM&I) symptom domains across neuropsychiatric, neurodegenerative and physical health disorders (priority: AD, MDD, obesity; others as relevant).
2. Identification and advancement of novel transdiagnostic candidate markers and endpoints toward validation; application of learnings to drug discovery to increase probability of success.
3. A clear roadmap for full regulatory and HTA validation of candidate markers and endpoints, accompanied by clinical best-practice guidelines and recommendations for diagnostic classification updates to expedite precision medicine adoption.
4. Deeper mechanistic understanding of the biological foundations of RM&I symptom domains and their roles in AD, MDD, obesity and other disorders, enabling generation of novel therapeutic approaches by industry.
5. Strengthened alignment between psychiatry, neurology and physical health disciplines, facilitating interdisciplinary dialogue among HCPs and specialists to optimise care for individuals with complex needs and comorbidities.
2. Identification and advancement of novel transdiagnostic candidate markers and endpoints toward validation; application of learnings to drug discovery to increase probability of success.
3. A clear roadmap for full regulatory and HTA validation of candidate markers and endpoints, accompanied by clinical best-practice guidelines and recommendations for diagnostic classification updates to expedite precision medicine adoption.
4. Deeper mechanistic understanding of the biological foundations of RM&I symptom domains and their roles in AD, MDD, obesity and other disorders, enabling generation of novel therapeutic approaches by industry.
5. Strengthened alignment between psychiatry, neurology and physical health disciplines, facilitating interdisciplinary dialogue among HCPs and specialists to optimise care for individuals with complex needs and comorbidities.
Funded areas
Scope Requirements
• Build on and extend an existing federated data platform – do not create a new platform or biorepository from scratch.
• Consolidate, curate and link high-quality multimodal datasets (retrospective, prospective, longitudinal) and samples across neuropsychiatric, neurodegenerative and physical health disorders, prioritising Alzheimer’s disease, major depressive disorder and obesity but including other conditions where RM&I symptoms are clinically significant.
• Ensure platform capabilities: data/sample discovery, access, interoperability, AI/ML-supported analysis and scalability for global research use.
• Integrate diverse data modalities: neurophysiology, imaging, behavioural, real-world, clinical, physiological, speech, patient-reported outcomes, molecular “-omics” and neuromodulation.
• Apply inclusive and equitable approaches to data representation and stakeholder engagement (gender, ethnicity, age).
• Prospectively test candidate markers/endpoints in clinical pilot case studies with defined contexts (patient selection, diagnosis, treatment monitoring) in transdiagnostic populations (AD, MDD, obesity).
• Collaborate with people with lived experience, carers, HCPs, regulators, HTA bodies and payers to co-design new diagnostic and treatment frameworks, clinical guidelines and training for healthcare system readiness.
• Ensure compliance with GDPR, IPR and ethical standards; post-project, provide open-access to the platform for ongoing research and validation.
• Consolidate, curate and link high-quality multimodal datasets (retrospective, prospective, longitudinal) and samples across neuropsychiatric, neurodegenerative and physical health disorders, prioritising Alzheimer’s disease, major depressive disorder and obesity but including other conditions where RM&I symptoms are clinically significant.
• Ensure platform capabilities: data/sample discovery, access, interoperability, AI/ML-supported analysis and scalability for global research use.
• Integrate diverse data modalities: neurophysiology, imaging, behavioural, real-world, clinical, physiological, speech, patient-reported outcomes, molecular “-omics” and neuromodulation.
• Apply inclusive and equitable approaches to data representation and stakeholder engagement (gender, ethnicity, age).
• Prospectively test candidate markers/endpoints in clinical pilot case studies with defined contexts (patient selection, diagnosis, treatment monitoring) in transdiagnostic populations (AD, MDD, obesity).
• Collaborate with people with lived experience, carers, HCPs, regulators, HTA bodies and payers to co-design new diagnostic and treatment frameworks, clinical guidelines and training for healthcare system readiness.
• Ensure compliance with GDPR, IPR and ethical standards; post-project, provide open-access to the platform for ongoing research and validation.
Additional Conditions for Applicants
Special Conditions
• Two-stage submission: stage 1 short proposals (20 pages), stage 2 full proposals (50 pages).
• Eligible participants: EU Member States, Horizon Europe Associated Countries; UK and Canada legal entities are eligible for funding in this topic.
• Minimum 45% industry contribution (IHI-specific eligibility).
• Specific annexes required: Type of Participants, Budget and Participant Type, Declaration of In-Kind Contributions, Clinical Studies (or declaration of none), Ethics (if applicable).
• JU retains the right to object to transfer or exclusive licensing of foreground.
• Availability/Accessibility/Affordability (“3 A”) exemption applies (does not apply to this topic).
• Compliance with Horizon Europe general Annexes on admissibility, evaluation, financial and operational capacity, exclusions, MGA v1.2.
• No development of new in vitro diagnostics or digital sensors in pilot clinical studies.
• Applicants must outline their approach to inclusive and equitable practices via a risk register and mitigation plan (data bias, stakeholder engagement, ethics, feedback mechanisms).
• Leverage outputs from previous/ongoing PPPs and consider synergies with the future European Genomic Data Infrastructure and European Brain Health Partnership.
• Eligible participants: EU Member States, Horizon Europe Associated Countries; UK and Canada legal entities are eligible for funding in this topic.
• Minimum 45% industry contribution (IHI-specific eligibility).
• Specific annexes required: Type of Participants, Budget and Participant Type, Declaration of In-Kind Contributions, Clinical Studies (or declaration of none), Ethics (if applicable).
• JU retains the right to object to transfer or exclusive licensing of foreground.
• Availability/Accessibility/Affordability (“3 A”) exemption applies (does not apply to this topic).
• Compliance with Horizon Europe general Annexes on admissibility, evaluation, financial and operational capacity, exclusions, MGA v1.2.
• No development of new in vitro diagnostics or digital sensors in pilot clinical studies.
• Applicants must outline their approach to inclusive and equitable practices via a risk register and mitigation plan (data bias, stakeholder engagement, ethics, feedback mechanisms).
• Leverage outputs from previous/ongoing PPPs and consider synergies with the future European Genomic Data Infrastructure and European Brain Health Partnership.
Important dates
Open from: 17/06/2025
Deadline:09/10/2025
Win your grant with Cogrant
How cogrant works
Smart Funding Fit Check
Instantly know if your project fits call criteria. Our system highlights strengths, gaps, and risks, so you only apply when your chances are real.
Intelligent Research Engine
Our research engine digs deeper than any founder could alone. It pulls data about your company, your market, and even your competitors - giving your proposal an edge backed by facts, not fluff.
Full Proposal Development
Our system builds your entire proposal from start to finish, ensuring every section is complete, coherent, and crafted to the highest quality. You focus on your vision — we deliver the winning document.
Expert Review
Our experts run a complete review before delivery, ensuring your draft proposal is accurate, well-structured, and polished. You’ll receive a high-quality draft that’s ready for your final touches before submission.
Our Numbers
Results that speak for themselves
70+
proposals prepared
€36.7M
total funding secured for clients
65%
win rate in highly competitive calls